Immune checkpoint blockade of programmed death-1 (PD-1) by monoclonal antibody drugs has delivered breakthroughs in the treatment of cancer. Nonetheless, smallmolecule PD-1 inhibitors could lead to increases in treatment efficacy, safety, and global access. While the ligand-binding surface of apo-PD-1 is relatively flat, it harbors a striking pocket in the murine PD-1/PD-L2 structure. An analogous pocket in human PD-1 may serve as a small-molecule drug target, but the structure of the human complex is unknown. Because the CC′ and FG loops in murine PD-1 adopt new conformations upon binding PD-L2, we hypothesized that mutations in these two loops could be coupled to pocket formation and alter PD-1's affinity for PD-L2. Here, we conducted deep mutational scanning in these loops and used yeast surface display to select for enhanced PD-L2 binding. A PD-1 variant with three substitutions binds PD-L2 with an affinity two orders of magnitude higher than that of the wild-type protein, permitting crystallization of the complex. We determined the X-ray crystal structures of the human triple-mutant PD-1/PD-L2 complex and the apo triple-mutant PD-1 variant at 2.0 Å and 1.2 Å resolution, respectively. Binding of PD-L2 is accompanied by formation of a prominent pocket in human PD-1, as well as substantial conformational changes in the CC′ and FG loops. The structure of the apo triple-mutant PD-1 shows that the CC′ loop adopts the ligand-bound conformation, providing support for allostery between the loop and pocket. This human PD-1/PD-L2 structure provide critical insights for the design and discovery of small-molecule PD-1 inhibitors.
Introduction
Immune checkpoint blockade of programmed death 1 (PD-1) and its ligand 1 (PD-L1) has dramatically increased progression-free survival for many cancers (1) (2) (3) . The first time that the FDA approved a cancer treatment based on a genetic biomarker rather than the primary site of origin was in 2017, when the monoclonal antibody (mAb) drug, pembrolizumab (Keytruda ® ), received approval for use in patients with microsatellite instability-high or mismatch repair deficient solid tumors (4, 5) . Indeed, mAb drugs inhibiting immune checkpoints have ushered in an exciting new chapter in oncology.
Nevertheless, there is a desire for small-molecule inhibitors of immune checkpoints. First, in general, small molecules are expected to penetrate more effectively than mAbs into the tumor microenvironment, perhaps enhancing efficacy (6) . In addition, if penetration into the brain is desired, small molecules can be effective (7, 8) . Second, there are rare but severe immune-related side effects of checkpoint inhibition that require immediate drug discontinuation (9) (10) (11) (12) . Since mAbs have long half-lives in the body (typically weeks) (13) , the treatment of such severe immunerelated side effects is primarily supportive. Small-molecule checkpoint inhibitors could offer convenient dosing (e.g., once per day) while allowing for prompt drug removal if desired (14) . Finally, small-molecule immune checkpoint inhibitors would facilitate cancer treatment in low-and middle-income countries by reducing production costs and eliminating the need for refrigeration during transportation and storage, in contrast to mAbs (15) . Despite substantial efforts (16, 17) , there are no well-characterized smallmolecule ligands for PD-1.
The ligand-binding surface of human PD-1 is generally flat, lacking pockets considered suitable for binding small molecules (18) . However, upon binding to PD-L1, a modest cavity forms on the ligand-binding surface of PD-1 (19) . A similar cavity forms in murine PD-1 upon binding of PD-L1 (20) . Importantly, when murine PD-1 binds a different ligand, PD-L2 (21) , this cavity extends ( Figures 1A-B ) to a volume comparable to that occupied by established small-molecule inhibitors (22) (23) (24) (25) . Unfortunately, this murine structure is insufficient to provide a structural model for the analogous pocket in the human PD-1/PD-L2 complex, as the human and murine PD-1 proteins share sequence identities of only 63% (26) .
Although the murine PD-1/PD-L2 structure was determined over a decade ago (21) , the structure of the human complex has not been reported. Our previous attempts to obtain diffraction-quality crystals of the human PD-1/PD-L2 complex were unsuccessful. Analyses of earlier structural studies (21, 26) revealed that formation of cavities on the ligand-binding surface of PD-1 is accompanied by changes in the structures of the CC′ and FG loops ( Figure 1C ). We therefore hypothesized that substitutions in these loops could have an allosteric effect on the conformations of PD-1 in the pocket region and alter its affinity for PD-L2. Using deep mutational scanning (27, 28) and yeast surface display (29) , we selected for CC′ and FG loop variants of human PD-1 with enhanced PD-L2 binding. We identified a triple-mutant PD-1 that binds PD-L2 with nanomolar affinity and is amenable to crystallization, both alone and as a complex. The resulting X-ray crystal structures confirm that a prominent pocket forms in human PD-1 upon binding of PD-L2 and support the notion of allostery between the pocket and the CC′ and FG loops. The pocket identified here in human PD-1 can serve as a template for virtual drug discovery (30) and opens up additional avenues for the discovery of small-molecule PD-1 inhibitors.
Results

Engineering human PD-1 loop variants with enhanced PD-L2 affinity
Substantial efforts by us and others (31) to crystallize the human PD-1/PD-L2 complex were previously unsuccessful. Earlier studies (18, 19, 21) indicated that the PD-1 ligand-binding interface consists of a hydrophobic core, the CC′ loop, and the FG loop ( Figure 2A) , and that formation of a complex with ligands results in loop movement and pocket formation in the hydrophobic core. We hypothesized that mutations in these two loops of PD-1 were coupled to pocket formation and could alter PD-1's affinity for PD-L2. Consistent with this hypothesis, we found that poly-glycine mutants of these loops in human PD-1 substantially decreased affinities for PD-L2 ( Figures S1A-B ).
Since we were particularly interested in the structure of the PD-1 pocket when bound to PD-L2, we maintained residues in the hydrophobic core and performed directed evolution exclusively in the CC′ loop (residues 70-78) and the FG loop (residues 127-133) of human PD-1. We used deep mutational scanning (27, 28) to construct loop-variant libraries with trinucleotides encoding each of 20 residues at each position. We next used yeast surface display (29) (Table S1 ) with a recombinant human PD-L2-human Fc fusion protein as the selection agent ( Figure 2B ). After two rounds of selection using magnetic-and fluorescence-activated cell sorting (MACS and FACS) ( Figure 2C ), we isolated human PD-1 loop-variant clones with single-residue substitutions. Substitutions at two residues were identified in the CC′ loop (N74G and T76P) and at one residue in the FG loop (A132V, A132L) ( Figure 2D ). In contrast, when we used the same yeast library and selected with PD-L1-Fc, we only isolated the A132 substitutions as high-affinity variants (Figures S1C-E), suggesting that the N74G and T76P variants are PD-L2-binding specific. We chose PD-1 T76P as a template to generate a second PD-1 loop variant library and selected for further enhancement of PD-L2 with our co-crystal structure. The high-affinity loop substitutions of PD-1 localize to the interface ( Figure 4B ). Among them, T76P and A132V make additional contacts to PD-L2 that likely contribute to the increase in affinity ( Figures S4E-H ).
X-ray crystal structures of human apo-PD-1 loop variants
To assist analyses of the conformational changes in PD-1 associated with PD-L2 binding, we crystallized two human apo-PD-1 loop variants (Table S2 ) and determined X-ray crystal structures at 1.2 Å and 1.4 Å resolution for PD-1 N74G T76P A132V (Figures S5A, S5C) and PD-1 T76P A132V ( Figures S5B, S5D ), respectively. Crystals of both variants contain a single PD-1 molecule per asymmetric unit, with space group P 32 2 1 ( Table 1 ). Both PD-1 variants were well defined by the electron density maps, with the notable exception of the CC′ loop discussed further below (Figures S5E-F). Superimposing the apo and PD-L2-bound PD-1 N74G T76P A132V structures resulted in a Cα R.M.S.D. of 1.6 Å.
The C′D loop of PD-1 (residues 83-92) is a major part of the pembrolizumab epitope (36) (37) (38) . This loop is not resolved in earlier structures of human PD-1 in the absence of pembrolizumab (19, 31, 39) , but is clear in both of our apo-PD-1 structures.
Our results indicate that the conformation of the loop changes substantially upon antibody binding ( Figure S5G ).
Formation of a prominent pocket in human PD-1 upon binding PD-L2 with an architecture distinct from the murine pocket
Our crystal structures of the human PD-1/PD-L2 complex and apo-PD-1 variants allowed us to examine formation of the human PD-1 pocket in the PD-1/PD-L2 interface. Although the human apo-PD-1 variant has a flat ligand-binding interface ( Figure 5A ), there are rearrangements in this interface upon binding PD-L2. These rearrangements involve residues in βC (F63, V64, N66, Y68), βF (L122, G124, I126), βG (I134, E136), and the C′D loop (E84) to form a deep and extended pocket ( Figure  5B ). Each of these residues in PD-1 is within 4.4 Å of a PD-L2 residue ( Figure S4I ). This pocket accommodates PD-L2 sidechains including the aromatic residues W110L2 and Y112L2 ( Figure 5C ).
Comparison of the PD-1 pockets in the human and murine PD-1/PD-L2 complexes revealed striking differences in pocket geometries. The human pocket adopts an open, funnel-shaped architecture. Compared to the murine pocket (Figures 1B, S6B-C), the human pocket has a wider entrance and a narrower exit ( Figure 5B ). The distinct pocket geometries arise from at least two factors. First, human PD-1 employs a different subset of interfacial residues to form the pocket than the murine version. Human PD-1 lacks an ordered βC′′ strand and thus the open pocket is formed by rearranging residues F63, V64, and E84. In contrast, the murine pocket is closed, with sidechains of A81 and S83 forming a boundary ( Figures S6A-B ). Second, several sequence variations exist among the residues that form the pocket. For example, V64 and Y68 in human PD-1 are substituted with M64 and N68 in murine PD-1, respectively (Figures 5B and S6B). To quantitatively evaluate the pocket dimensions, we measured pocket volumes using POCASA 1.1 (40) . The human and murine pockets have volumes of 170 Å 3 and 220 Å 3 , respectively. Notably, these pockets are comparable in size to other protein cavities with established small-molecule inhibitors (160-800 Å 3 ) (22) (23) (24) (25) .
We compared our human PD-1/PD-L2 structure ( Figure S6E ) with the previously determined human PD-1/PD-L1 structure (19) (Figure S6F ). Superimposing the two structures resulted in a Cα R.M.S.D. of 1.5 Å for PD-1 residues. Binding PD-L1 triggers formation of a much smaller cavity in human PD-1, with a volume of 80 Å 3 ( Figure S6D ). PD-L1 lacks a large aromatic sidechain corresponding to W110L2, so the PD-1 rearrangement only involves accommodation of a small subset of the interfacial residues, including the sidechain of Y123L1, which corresponds to PD-L2 residue Y112L2 ( Figures S6E-H) . These results indicate that the core of the human PD-1 interface has remarkable structural plasticity, with the ability to form pockets with varied dimensions to interact with different PD-1 ligands.
The CC′ loop in triple-mutant PD-1 adopts a ligand-bound conformation in the absence of ligand
We also detected conformational changes in the CC′ and FG loops when human PD-1 binds PD-L2 ( Figures 6A-B ). Earlier studies reported that the CC′ loop undergoes a substantial conformational change when human PD-1 binds PD-L1 (19, 39) . This CC′ loop conformational change is even larger in the human PD-1/PD-L2 structure reported here ( Figures 6A and S7A ). Strikingly, in the absence of ligands, the CC′ loop conformations of the PD-1 triple and double mutants resemble those of the ligandbound conformations ( Figure S7A ). For example, a 4.8 Å shift occurs between the Cα of T76 and P76 in the PD-1 triple mutant of apo-PD-1 ( Figure 6A ). When the PD-1 triple mutant binds PD-L2, the sidechain of P76 maintains the same conformation as the unbound protein ( Figure 6A ). An increased population of the ligand-bound conformations of the mutant apo-PD-1 proteins is consistent with increased association constants (kon) of the PD-1 variants ( Figure 3C and S2C).
In contrast, the conformations of the FG loop are the same in all three apo-PD-1 structures: one with an A132L substitution in the FG loop (31) and the triple and double mutants described here ( Figure S7B ). Upon binding PD-L1 (19) , there are no substantial conformational changes in the FG loop ( Figure 6B ). There is, however, a drastic shift in the FG loop conformation upon binding PD-L2 ( Figures 6B and S7B ).
Structural plasticity of the human PD-1 ligand-binding interface
To further investigate how the observed loop changes are associated with pocket formation, we superimposed the apo and PD-L2-bound structures of our human triplemutant PD-1 ( Figure 6C ). Upon binding PD-L2, a large conformational change occurs in the PD-1 ligand-binding interface ( Figure 6C ). A three-residue shortening of βC occurs ( Figure S7C ), and βC and βF move apart to create a deep cleft ( Figure 6C ). The rearrangements in the pocket propagate to the edge of the FG loop, resulting in a remarkable 8.2 Å lateral shift ( Figure 6C ).
We note that the overall change is less dramatic in murine PD-1 ( Figure S7D ). The closed architecture of the murine pocket does not require flipping of residues E84 and F63, as seen in human PD-1, and there is no secondary structure change in βC in murine PD-1 ( Figure S7E ). Taken together, our results provide a structural basis for systematic rearrangements at the human PD-1 ligand-binding interface that couple pocket formation and changes in the loops of PD-1 when it binds PD-L2.
Discussion
A prominent pocket forms in human PD-1 upon binding PD-L2. This pocket has a volume of 170 Å 3 , comparable to pockets that bind small-molecule drugs (22) (23) (24) (25) . The structure of this pocket is quite distinct from the corresponding pocket in murine PD-1 bound to PD-L2 (21) .
We speculate that this pocket represents an attractive drug target. How would a pocket-binding drug bind to a flat protein surface? We conceptualize an ensemble of PD-1 conformations ( Figure S8 ) in which the predominant species of apo-PD-1 has a flat ligand-binding surface (Ki < 1). A pocket-binding drug will stabilize the PD-1 conformation containing the pocket (Kiii). Drug binding via an induced-fit mechanism (Kiv > 1) can also occur.
The human PD-1/PD-L2 structure reported here will facilitate virtual drug screening to identify potential lead compounds (e.g., (30) ). Specifically, we envision a small molecule binding to PD-1 contacting all or many of the residues that form the pocket, particularly F63, V64, N66, Y68, E84, L122, G124, I126, I134, and E136 in a conformation similar to that formed in the complex with PD-L2 ( Figure 5B ). In addition, the structures of the indole and phenyl rings and neighboring sidechains of PD-L2 when bound to the pocket ( Figure 5C ) are potentially useful starting points for the design of fragment-based screening scaffolds (41, 42) .
Since the PD-1 pocket is not populated substantially in the absence of PD-L2, it is not straightforward to use traditional drug-screening methods to identify small molecules that bind the pocket. Nonetheless, we speculate that conformational changes in the CC′ and FG loops and formation of pockets in the ligand-binding interface of PD-1 are thermodynamically coupled ( Figure 7 ) and that this coupling can be used to enable drug-discovery efforts. We envision that PD-1 exists in an ensemble of conformations in the absence of ligands, populating predominantly structures that contain a flat ligandbinding face (i.e., K1 < 1). PD-1 molecules with a pre-formed pocket have a higher affinity for PD-L2 (K3 > K2). Thermodynamics dictates that K1K3 = K2K4, so K4 > K1. In this model, the PD-1 loop variants studied here increase K1, and lead to a higher proportion of apo-PD-1 in the PD-L2-bound conformation.
The higher association constants (kon) for binding ligands by the mutant PD-1, as compared to wild-type PD-1 ( Figures 3C and S2C ), support this model. Such kinetic properties are consistent with an increased fraction, relative to wild-type PD-1, of unliganded mutant PD-1 molecules that are in a ligand-bound conformation ((34); see however, (35) ). In addition, the CC′ loop shifts toward the PD-L2-bound conformation in the apo-PD-1 triple and double mutants ( Figure S7A ). (While there are only minimal changes in the pocket in both apo-PD-1 mutants ( Figure 5A ), the pocket residues and a neighboring FG loop have substantial crystal contacts in the lattice ( Figure S5H ) that likely interfere with conformational changes.)
Coupling between the pocket and the loops would stabilize the pocket in the absence of a ligand, for example if the loops were held in their PD-L2-bound conformations with antibodies or aptamers. Alternatively, or in addition, new mutations (e.g., amino acid replacements, insertions and/or deletions) could be selected for or designed to induce conformational changes in the loops. This coupling could therefore enable more traditional approaches to small-molecule drug discovery, such as high-throughput screening (43, 44) and/or the discovery of allosteric regulators of PD-1 activity. More generally, our work has implications for enhancing discovery of smallmolecule inhibitors of other "undruggable" protein-protein interactions.
Materials and Methods
Additional information is provided in the SI Appendix, SI Materials and Methods.
Yeast surface display
Deep mutational scanning of the CC′ and FG loops of human PD-1 was performed using a previously described PCR-based method (27) . PD-1 loop variant libraries were constructed using the Saccharomyces cerevisiae EBY100 strain (ATCC) (Table S1), by fusing PD-1 to the C-terminus of Aga2 under the GAL1 promoter. MACS and FACS experiments were performed using recombinant human PD-L2-Fc or PD-L1-Fc proteins.
Bio-layer interferometry
Bio-layer interferometry was performed on an Octet RED96 ® system at 30 °C in a buffer of 150 mM NaCl, 20 mM HEPES:NaOH pH 7.4, 0.1% bovine serum albumin, and 0.05% Tween 20. Human PD-1-Fc proteins were loaded onto anti-human IgG Fc capture (AHC) biosensors, associated in defined concentrations of human PD-L2-His6 or PD-L1-His6 proteins, and then dissociated in buffer.
Protein crystallization and X-ray crystallography
The human apo-PD-1 N74G T76P A132V and human apo-PD-1 T76P A132V proteins (Table S2) were over-expressed in and refolded from the inclusion bodies of Escherichia coli BL21(DE3) (Invitrogen TM ). The human apo-PD-1 N74G T76P A132V protein was crystallized in 100 mM NaCl, 100 mM Tris:HCl pH 8.0, and 27% (w/v) PEG-MME 5,000. The human apo-PD-1 T76P A132V protein was crystallized in 100 mM NaCl, 100 mM Tris:HCl pH 8.0, and 36% (w/v) PEG 3,350. The human PD-1 N74G T76P A132V and human PD-L2 IgV protein complex (Table S2 ) was produced using the human Expi293F cell line (Gibco TM ). The complex was crystallized in 200 mM magnesium acetate and 10% (w/v) PEG 8000. All X-ray diffraction data were collected at SSRL beam lines 12-2 or 14-1, and processed using HKL-3000 (45) . Molecular replacement, refinement, and density modification were performed in Phenix (46) and model building in Coot (47) .
Accession number
Coordinates and structure factors for the human PD-1 N74G T76P A132V / PD-L2 IgV complex, human apo-PD-1 N74G T76P A132V , and apo-PD-1 T76P A132V will be deposited in the RCSB Protein Data Bank (http://www.rcsb.org). Accession PDB IDs will be available after deposition. Structures are available immediately at https://peterkimlab.stanford.edu. Frequency (%) 
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Figure 7 Model for coupling of pocket formation with loop movements in PD-1
A thermodynamic cycle for PD-1 binding PD-L2. For clarity, only two of the states in the conformational ensemble of apo-PD-1 (top) are depicted. In one of these states (left) the ligandbinding interface is flat. In the second state (right) a pocket is formed and the loops have moved. Mutations or external agents (e.g., antibodies) could stabilize the loops in the PD-L2 bound conformation (i.e., increase K 1 ), thereby increasing the population of apo-PD-1 molecules in the bound conformation. Equilibrium constants for each step in the thermodynamic cycle are indicated (see Discussion). 
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Deep mutational scanning
Deep mutational scanning of the CC′ and FG loops was performed using a previously described PCR-based method (1) . For the amplicon, we used the cDNA encoding human PD-1 The vector backbone was generated by PCR to linearized pST892 using an OST941 PD1 P21 reverse primer and an OST880 PD-1 E150 forward primer. 16 μg of purified inserts were combined with 4 μg of purified vector backbone. The DNA mixtures were precipitated at -80 o C for 2 hours after mixing with 1:10 volume of 3.0 M NaOAc and three-time volume of 100% EtOH. The DNA pellet was collected by centrifugation at 21,300 rcf for 30 min at 4 o C, and then air-dried.
Assembly of the PD-1 loop variant libraries
The PD-1 variant libraries of the CC′ loop, the FG loop, and the CC′ and FG loops were generated separately. Saccharomyces cerevisiae EBY100 strain (ATCC) ( Table S1) were then washed with 1 mL and resuspended in 100 μL of the selection buffer. Flow cytometry was performed using a BD Accuri™ C6 Flow cytometer. 10,000-100,000 events were recorded and analyzed for clonal expression (the FL1 channel) and bait binding (the FL4 channel). Graphs of flow cytometry were generated using FlowJo. 
Protein expression and purification
Bio-layer interferometry
Bio-layer interferometry was performed on an Octet RED96 ® system (Pall ForteBio) in a buffer of 150 mM NaCl, 20 mM HEPES:NaOH pH 7.4, 0.1% BSA and 0.05% Tween 20 at 30 o C at a shaking speed of 1,000. The human PD-1-Fc proteins were loaded onto anti-human IgG Fc capture (AHC) biosensors with a load threshold of 0.8 nanometer.
After loading, the biosensors were baselined, and associated in defined concentrations of human PD-L1-His6 or PD-L2-His6 proteins for 120 seconds, and then dissociated in buffer for 120 seconds. The baseline-corrected binding curves were analyzed with GraphPad Prism 8.
Protein purification for crystallization
For the human apo-PD-1 N74G T76P A132V and human apo-PD-1 T76P A132V proteins, cDNA encoding PD-1 residues 33-150 with substitutions of C93S N74G T76P A132V or C93S T76P A132V were subcloned into a pET23d vector. The C-terminus of PD-1 is fused with a GS linker and followed by a Strep-tag®II (WSHPQFEK) for affinity purification (Table S2) For the human PD-1 N74G T76P A132V and human PD-L2 IgV protein complex, human cDNA encoding PD-1 residues 33-150 with substitutions of C93S N74G T76P A132V and N-linked glycosylation mutations of N49S N58S N74D N116D, and human cDNA encoding PD-L2 residues 1-123 with N-linked glycosylation mutations of N37D N64D were separately subcloned into pADD2 vectors. The N-terminus of the PD-1 protein was fused to a signal sequence of MGWSCIILFLVATATGVHS before residue 33. The Cterminus was fused to a PEA tag after amino acid E150, which together consisted of a C-tag for affinity purification (Table S2 ). Both plasmids were combined at a 1:1 ratio and used for co-transfecting Expi293F cells. Supernatants of the cell culture were collected and incubated with CaptureSelect C-tagXL affinity matrix (Thermo Fisher Scientific). 
Protein crystallization
The human apo-PD-1 N74G T76P A132V protein was crystallized at room temperature in a hanging-drop vapor diffusion system by mixing 1 μL of 9.8 mg/mL of protein with 1 μL of 1 mL reservoir solution containing 100 mM NaCl, 100 mM Tris:HCl pH 8.0, 27 % (w/v) PEG-MME 5,000. Crystals were transferred into the same solution supplemented 
X-ray crystallography
For the human apo-PD-1 N74G T76P A132V crystal, X-ray diffraction data was collected to 1.18 Å at the Stanford Synchrotron Radiation Lightsource (SSRL) beam line 12-2 of SLAC National Accelerator Laboratory. The crystal belonged to the space group P 32 2 1 with unit cell dimensions a=46.2 Å b=46.2 Å c=89.3 Å α=90° β=90° γ=120° (Table 1) .
For the human apo-PD-1 T76P A132V crystal, X-ray diffraction data was collected to 1.42 Å at the SSRL beam line 14-1. The crystal also belonged to space group P 32 2 1 with unit cell dimensions a=46.2 Å b=46.2 Å c=89.4 Å α=90° β=90° γ=120° (Table 1) .
For the human PD-1 N74G T76P A132V /PD-L2 IgV cocrystal, X-ray diffraction data was collected to 1.99 Å at the SSRL beam line 12-2. The crystal belonged to space group P 21 21 21 with unit cell dimensions a=41.3 Å b=67.8 Å c=89.7 Å α=90° β=90° γ=90° ( Table 1 ).
All diffraction data were processed using HKL-3000 (2) . The structure of human apo-PD-1 N74G T76P A132V was solved using Phaser in Phenix (3) by molecular replacement with the human apo-PD-1 A132L structure (PDB: 3RRQ) as a search model. The structure of human apo-PD-1 T76P A132V was solved by molecular replacement with the human apo-PD-1 N74G T76P A132V structure. The structure of the human PD-1 N74G T76P A132V /PD-L2 IgV complex was solved by molecular replacement with the human apo-PD-1 N74G T76P A132V structure, and the IgV domain of murine PD-L2 from the murine PD-1/PD-L2 structure (PDB: 3BP5). Model refinement and density modification were performed in Phenix (3). Model building was performed using Coot (4) . Structural images were generated with PyMOL (Schrödinger). Pocket volumes and volume-depths were measured using POCASA 1.1 (5) , with parameter settings of 6 Å for probe radius, 16 for single point flag, 18 for protein-depth flag and 1.0 Å for grid size. Figure 5B . Distance measurements were generated by COCOMAPS. . In (B) , an apohuman PD-1 WT NMR structure (PDB: 2M2D, state 1, blue white) is also overlaid. Dashed arrow shows a C shift for P130 of 8.2 Å from apo-PD-1 N74G T76P A132V to PD-L2-bound PD-1 N74G T76P A132V . Residues 71-74 of the CC loop in apo-PD-1 N74G T76P A132V are unresolved. Modest electron density for the mainchain atoms of these unresolved residues is observed in apo-PD-1 T76P A132V . WT, wildtype; NMR, nuclear magnetic resonance. (C) Topology diagrams of the ligand-binding interface of human apo-PD-1 N74G T76P A132V (left) and PD-L2-bound human PD-1 N74G T76P A132V (right). C residues F63, V64, and L65 unfold into a coil upon PD-L2 binding. (D) Overlay of ribbon diagrams of murine PD-1 between apo-PD-1 (pale yellow) and PD-L2-bound PD-1 (PDB: 3BP5, dark green). A subset of pocket residues that undergo main-chain rearrangements are indicated with sticks. The FG loop shift of 6.0 Å in murine PD-1 was measured using the C of P130. (E) Topology diagrams of the ligand-binding interface of murine apo-PD-1 (left) and PD-L2-bound murine PD-1 (right). F residues I126 and S127, as well as G residues K133, I134, and E135, unfold into a coil upon PD-L2 binding.
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Figure S8 Thermodynamic cycle for binding of a small molecule to the PD-1 pocket
For clarity, only two of the states in the conformational ensemble of apo-PD-1 (top) are depicted. In apo-PD-1 the predominant species has a flat binding surface (K i < 1). A pocket-binding drug will stabilize the PD-1 conformation containing the pocket (K iii ). Drug binding via an inducedfit mechanism (K iv > 1) can also occur.
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